Andrew Wong was the Global Head of Bayer Co. Labs and oversaw the organization’s business development, in-licensing and start-up innovations.  Andrew was formerly the Vice-President of Early Innovation Partnering & Transactions at Johnson & Johnson Innovation, Asia Pacific, where he managed early-stage business development transactions and collaboration management activities in the region across Johnson & Johnson’s three business sectors. Prior to J&J, Andrew was Senior Vice-President, Corporate Business Development at Auransa Inc., a leading venture-backed precision medicine biopharmaceutical company. Before that, Andrew was Vice-President, Business Development at SciClone Pharmaceuticals. Andrew also previously played roles at Alexza Pharmaceuticals, ProQuest Investments, Lehman Brothers, Dendreon Corporation and Life Science Economics with various responsibilities from Head of Corporate Development to Senior Equity Research and Senior Business Development Analyst. Andrew has over 28 years of life-science business development and finance experience and holds an MBA from the Wharton School at University of Pennsylvania and a BA in biology from Occidental College.

Andy is a pharmacologist, that has been a drug hunter, with a “golden touch” for the last 45 years. His experience guiding the preclinical development of Enzalutamide and Talazoparib, while at Medivation, is helping us develop OC-3 as a differentiated PARP1 inhibitor, specifically in prostate cancer.  His leadership roles at Auransa, Medivation, Scios and CalBio, produced four marketed products in oncology and cardiovascular disease.

Son is a medicinal chemist with 20 years of experience, having started his professional career at Celera Genomics in 2005. From 2006-2016, Son was employed at Genelabs, Verseon and Medivation in roles with increasing responsibilities. From 2016-2022, he was Head of Chemistry at SPARCBIO and led the medicinal chemistry teams which discovered NUV-422 and NUV-868. Son co-founded 1cBio in 2022, together with Jit Chakravarty and Sunny Chen. Since 2016, he has advised and supported several seed-stage companies regarding the design and synthesis of new chemical matter for their preclinical programs. In many cases, Son and his team were directly involved with the invention and discovery of the lead series and molecule. Son received his Ph.D. in Chemistry from the University of Illinois, Urbana-Champaign.

Prashant has over 30 years of experience in all areas of finance including venture funding, FP&A, accounting, financial analysis, valuation modeling, M&A/corporate development, strategy, audit and treasury. He has a thorough understanding of finance and accounting principles through MBA in Finance from Southern Methodist University, Dallas, TX and Chartered Accountancy certification (CPA foreign equivalent). At Liberty he worked initially as Vice President & General Manager of Strategy & Business Development and then Deputy Group Head of M&A. At Aviva, Prashant was Head of Strategic Investments and was also supporting the Corporate Venture Fund. Prashant served as corporate finance and accounting consultant for SPARCBIO for 2 years and has been with 1cBio since inception in February 2022.